AstraZeneca and its biologics research arm MedImmune have signed a five-year strategic research collaboration with Ethris, an mRNA-based therapeutics company specialising in pulmonary disease.

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

Platelets are cells that help your blood clot, and it was so unusual to see blood clots combined with low platelet levels, that experts coined a new medical term: vaccine-induced thrombosis with ...

COVID-19 vaccination is associated with a reduced risk for most cardiovascular events, but with slightly increased risks of extrasystoles and transient ischemic attack, as well as myocarditis and ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a new AstraZeneca-partnered candidate for heart ...

Reading ‘Australia’s Pandemic Exceptionalism’ and this official response report is essential for anyone likely to have ...

Several authors disclosed ties to pharmaceutical companies, including AstraZeneca and Pfizer. Abstract/Full Text ...

Antiviral Immunoglobulin Market. The global antiviral immunoglobulin market was valued at USD 4.6 billion in 2022 and is ...

"Our study provides compelling evidence that repeated mRNA vaccinations can improve ... Ablynx, ALK, ArgenX, AstraZeneca, Bekaert Textiles, Genentech, GSK, Hall Allergy, Medtronic, Novartis ...

At an event held in the House of Lords on 5th November, The Trade Facilitation Commission released their detailed report and ...